|
Hallo, hier habe ich etwas für Zocker. Wer einsteigen will - bitte in den USA Charttech. kann es schnell Richtung 0,50 $ gehen. Dies ist aber keine Kaufempfehlung. WKN: 885701 Sep. 8, 2003 11:53 ET Market Open Common Stock Market: OTCBB Last Sale $ 0.228 Change Net / % 0.088 62.86% Best Bid / Ask $ 0.21 $ 0.23 Today`s High / Low $ 0.28 $ 0.16 Share Volume 1,553,100 Previous Close $ 0.14 52 Wk High / Low $ 0.31 $ 0.05 Neoprobe Receives Marketing Clearance for Quantix/OR in United States; Quantix/OR To Be Delivered to Clinical Sites DUBLIN, Ohio, Sep 8, 2003 (BUSINESS WIRE) -- Neoprobe Corporation (OTCBB:NEOP), today announced that it had received clearance from the United States Food and Drug Administration to begin commercial marketing of the Quantix/OR(TM) system for the intraoperative measurement of blood flow. The Quantix/OR received marketing clearance under a U.S. FDA 510(k) application. David Bupp, Neoprobe`s President and CEO, said, "the marketing clearance of the Quantix/OR will allow us to commence the clinical evaluation of the Quantix/OR at leading institutions in the United States. The activity at institutions in United States will supplement the evaluations already underway in Europe and Asia and will support our efforts to develop a U.S. market for the Quantix/OR through one or more established national sales representative organizations." Dr. Richard Orahood, Neoprobe`s Medical Director, said, "the commencement of clinical evaluation of the Quantix/OR will be an important next step in the commercialization of the Quantix/OR. To date, the clinical evaluations in Europe by leading cardiothoracic surgery departments have shown the important innovation represented by the Quantix technology." The first evaluating site for the Quantix/OR in the United States will be Boston University Medical Center. Dr. Oz Shapira, Clinical Director of Cardiothoracic Surgery at Boston University said, "our research with the Quantix/OR in animal studies makes us confident that the Quantix/OR will permit easy and accurate measurement of blood flow volume in a variety of clinical settings." The Quantix/OR is designed to allow cardiothoracic and vascular surgeons to measure blood flow in a simple and real-time manner during intraoperative procedures. Quantix/OR consists of an angle-independent ultrasound probe that obtains signals directly from the blood vessel and measures blood flow in the vessel regardless of vessel size. The Quantix/OR simultaneously measures the internal diameter of the blood vessel and the velocity profile of the internal blood to calculate volume blood flow. About Neoprobe Neoprobe develops and provides innovative surgical and diagnostic products that enhance patient care by meeting the critical decision making needs of healthcare professionals. Neoprobe`s current line of gamma detection systems is widely used for intraoperative lymphatic mapping (ILM), an emerging standard of care technology for breast cancer and melanoma and the detection of radiopharmaceuticals applied throughout the human body`s tissues and organs. Neoprobe also holds significant interests in the development of related biomedical systems and agents. The Company`s strategy is to deliver superior growth and shareholder return by maximizing its strong position in gamma detection technologies and diversifying into new, synergistic biomedical markets through continued investment and selective acquisitions. With the 2001 acquisition of Cardiosonix Ltd., Neoprobe expanded its product portfolio to include blood flow measurement products. Cardiosonix is engaged in the early stages of commercializing the Quantix(TM) family of flood flow measurement products. Cardiosonix` products are designed to be used by neurosurgeons, cardiovascular surgeons and critical care physicians. Statements in this news release which relate to other than strictly historical facts are forward-looking statements, and as such are subject to risks and uncertainties, including those detailed in the Company`s most recent Annual Report on Form 10-KSB and other Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements. SOURCE: Neoprobe Corporation Neoprobe Corporation Brent L. Larson, 614-793-7500 or The Trout Group Jonathan Fassberg, 212-437-9007 http://www.businesswire.com Today`s News On The Net - Business Wire`s full file on the Internet with Hyperlinks to your home page. Copyright (C) 2003 Business Wire. All rights reserved. Gruß DmComeBack |
|
| aus der Diskussion: | Neoprobe + 62%, höchster Umsatz seit 2000 (nur für Zocker) |
| Autor (Datum des Eintrages): | DmComeBack (08.09.03 18:19:19) |
| Beitrag: | 1 von 14 (ID:10675432) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |